ACST Acasti Pharma, Inc.

+0.19  (15.08%)
Previous Close 1.26
Open 1.43
Price To book 0.91
Market Cap 15.53M
Shares 10,712,000
Volume 1,653,888
Short Ratio 0.34
Av. Daily Volume 193,931

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated by the end of 2017.
CaPre (TRIFECTA trial)

Latest News

  1. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q3, 2017 By the Numbers : January 16, 2017
  2. Acasti reports 3Q loss
  3. Acasti reports 3Q loss
  4. Acasti Pharma Reports Third Quarter 2017 Financial Results
  5. Acasti Pharma Appoints Linda O'Keefe as Chief Financial Officer
  6. Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV
  7. Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre
  8. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q2, 2017 By the Numbers : October 14, 2016
  9. Acasti Pharma Reports Second Quarter 2017 Financial Results
  10. McDonald’s Corporation (MCD), AcelRx Pharmaceuticals Inc. (ACRX) & More: Here’s Why These Stocks Are Trending Today
  11. Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
  12. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q1, 2017 By the Numbers : July 22, 2016
  13. Acasti Announces the Election of its Directors, Change of Fiscal Year End and Other Related Matters Passed at its AGM
  14. Acasti Announces First Quarter Results
  15. ACASTI PHARMA INC. Financials
  16. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q4, 2016 By the Numbers : June 1, 2016
  17. Acasti Announces Grant of Stock Options
  18. Acasti Announces Fourth Quarter and Fiscal Year Results
  19. Jan D'Alvise Appointed President & CEO of Acasti Pharma
  20. Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements